CSL Seqirus' adjuvanted influenza vaccine Fluad is now approved in Australia for active immunisation against flu in people aged 50 and over.
Registered and funded since 2018 for adults aged 65 and over on the NIP, data in adults aged 50-64 years has shown higher antibody titres compared with nonadjuvanted vaccines, particularly against vaccine A-strains, for up to nine months postvaccination.
"Enhanced influenza vaccines, including Fluad, are preferentially recommended by ATAGI over standard-dose vaccines for those aged 65 and over," said Dr Jules Bayliss, vaccines medical director for CSL Seqirus.
"The 50 registration for Fluad means that more people will be able to access this vaccine if they choose."
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Mar 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Mar 26
